Pomalidomide-induced lung injury: A case report.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
13 Jan 2023
13 Jan 2023
Historique:
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
ppublish
Résumé
Pomalidomide is an immunomodulatory imide drug used in multiple myeloma and in Kaposi sarcoma. A 72-years-old male, treated for multiple myeloma with dexamethasone, pomalidomide and daratumumab, presented dyspnea, hypoxemia, biological inflammatory syndrome, ground glass opacities on computed tomography scan (CT-scan) and lymphocytic and eosinophilic alveolitis, with no specific cytologic or microbiological findings, 2 months after pomalidomide initiation. Antibiotics were started after bronchoscopy. No improvement was noted in dyspnea and biological inflammatory syndrome after 5 days of treatment. Pomalidomide was then discontinued, with continuation of Daratumumab-Dexamethasone, resulting in a rapid recovery of symptoms and CT-scan anomalies. No recurrence of dyspnea was observed during the 15 months of follow-up. Pomalidomide-induced lung injury. Pomalidomide-induced lung injury is a rare and serious adverse event that can occur early after Pomalidomide introduction. As pomalidomide use is increasing, the identification of drug toxicity as a possible cause of lung injury appears important. We report a rapid recovery of symptoms and CT-scan anomalies after pomalidomide discontinuation.
Identifiants
pubmed: 36637962
doi: 10.1097/MD.0000000000032473
pii: 00005792-202301130-00047
pmc: PMC9839242
doi:
Substances chimiques
pomalidomide
D2UX06XLB5
Dexamethasone
7S5I7G3JQL
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e32473Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Chest. 2007 May;131(5):1572-4
pubmed: 17494808
Drug Des Devel Ther. 2017 Aug 22;11:2399-2408
pubmed: 28860711
J Clin Oncol. 2004 Aug 15;22(16):3269-76
pubmed: 15249589
Blood. 2010 Oct 28;116(17):3227-37
pubmed: 20651070
Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):447-461
pubmed: 31060991
Pediatr Blood Cancer. 2021 Feb;68(2):e28756
pubmed: 33025730
Am J Ther. 2021 Jan-Feb 01;28(1):e143-e144
pubmed: 33369914
Blood. 2018 Nov 22;132(21):2240-2248
pubmed: 30262659
N Engl J Med. 1999 Nov 18;341(21):1565-71
pubmed: 10564685
Lancet Oncol. 2013 Oct;14(11):1055-1066
pubmed: 24007748
Int J Hematol. 2012 Feb;95(2):223-4
pubmed: 22198829
Int J Tuberc Lung Dis. 2018 Nov 1;22(11):1383-1386
pubmed: 30355421
Drugs. 2013 May;73(6):595-604
pubmed: 23572409
Am J Med Sci. 2015 Sep;350(3):241-2
pubmed: 26200951
Blood. 2016 Jul 28;128(4):497-503
pubmed: 27226434
Onkologie. 2010;33(5):249-52
pubmed: 20502059
J Clin Oncol. 2016 Dec;34(34):4125-4131
pubmed: 27863194
Chest. 2011 Aug;140(2):529-533
pubmed: 21813533